An Update on Monoclonal Antibody Therapy to Treat Moderate-to-Severe Asthma: Benefits, Choices, and Limitations

Moderate or severe asthma is a complex disease process clinically manifesting as at least partially revers-ible airway obstruction due to airway hyperresponsiveness. Asthma therapy was based primarily on symp-tom control until recent studies of its mechanisms have led to a host of new targeted, safe, and effective therapies. These biologic therapies directly attack culprit inflammatory mediators at the molecular level. In this article we review currently available biologic agents for the treatment of moderate-to-severe asthma. We provide information deemed necessary to optimally consult with an asthma specialist to choose, assist in financial arrangements for, and coordinate the use of these new, promising, Food and Drug Administration-approved biologic agents. We will also briefly review the molecular pathways targeted with each class of biologic to provide a more in-depth understanding of why these targeted thera-pies are effective. These biologics are the first of many to come that modify newly discovered components of the immune system with which many physicians are unfamiliar.& COPY; 2023 Elsevier Inc. All rights reserved. & BULL; The American Journal of Medicine (2023) 136:738-744